Perceptive Advisors portfolio · Q2 2026
Perceptive Advisors LLC · CIK 0001224962 ·13F filings on SEC EDGAR
In Q2 2026, Perceptive Advisors LLC reported 109 positions worth $6.7B. Its largest holding was PRAX at 10.2% of the portfolio, and the top 10 made up 47%. Its largest new position was ASND ($310.4M), and it sold out of 04351P101.
- NEW 29
- ADD 30
- REDUCE 26
- EXIT 14
Portfolio map
Each box is a position sized by its value. Color shows the change in shares from the previous quarter. The smallest 69 positions are grouped as one box.
Portfolio history
Q4 2025 to Q2 2026, 3 quarters
Weight of the largest holdings
The 7 holdings with the highest weight in any quarter shown, stacked with all others to 100%.
Holding timeline
Shade shows the weight in each quarter. A blank cell means the holding was not reported that quarter.
Holdings
Click a holding to see its price chart with the quarters the investor bought or sold.
| Name | Weight | Avg. cost (est.) | Latest price | Gain/loss | Value |
|---|---|---|---|---|---|
PRAX PRAXIS PRECISION MEDICINES I | 10.23% | $112.81 | $291.23 | +158.2% | $592.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SYRE SPYRE THERAPEUTICS INC | 5.76% | $39.46 | $89.03 | +125.6% | $384.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CELC CELCUITY INC | 5.02% | $37.50 | $79.52 | +112.0% | $254.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ASND ASCENDIS PHARMA A/S | 4.66% | $266.72 | $227.83 | -14.6% | $265.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RYTM RHYTHM PHARMACEUTICALS INC | 4.31% | $101.51 | $95.22 | -6.2% | $246.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ROIV ROIVANT SCIENCES LTD | 4.30% | $14.52 | $36.57 | +151.8% | $295.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RLAY RELAY THERAPEUTICS INC | 3.96% | $12.45 | $18.05 | +44.9% | $254.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TVTX TRAVERE THERAPEUTICS INC | 3.20% | $23.74 | $58.88 | +148.0% | $221M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KARD KARDIGAN INC | 2.94% | $23.85 | $14.75 | -38.2% | $121M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NUVL NUVALENT INC-A | 2.93% | $51.19 | $123.50 | +141.2% | $195.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EWTX EDGEWISE THERAPEUTICS INC | 2.67% | $21.59 | $40.60 | +88.0% | $177.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
APGE APOGEE THERAPEUTICS INC | 2.61% | $48.89 | $132.73 | +171.5% | $173.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AMLX AMYLYX PHARMACEUTICALS INC | 2.25% | $4.86 | $29.10 | +498.7% | $242.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MGTX MEIRAGTX HOLDINGS PLC | 2.19% | $13.25 | $11.00 | -17.0% | $118.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ORKA ORUKA THERAPEUTICS INC | 1.92% | $20.79 | $83.29 | +300.5% | $112M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
INBX INHIBRX BIOSCIENCES INC | 1.85% | $24.45 | $100.08 | +309.4% | $129.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PTGX PROTAGONIST THERAPEUTICS INC | 1.81% | $43.67 | $140.89 | +222.6% | $138.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SLDB SOLID BIOSCIENCES INC | 1.79% | $6.95 | $7.23 | +4.0% | $86.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ZYME ZYMEWORKS INC | 1.64% | $19.18 | $26.49 | +38.1% | $110.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TNGX TANGO THERAPEUTICS INC | 1.58% | $26.95 | $24.95 | -7.4% | $84.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMTX IMMATICS NV | 1.58% | $10.71 | $8.78 | -18.0% | $91.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NRIX NURIX THERAPEUTICS INC | 1.57% | $17.46 | $23.71 | +35.8% | $102.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BCRX BIOCRYST PHARMACEUTICALS INC | 1.55% | $9.13 | $8.33 | -8.7% | $85.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMD REVOLUTION MEDICINES INC | 1.48% | $143.15 | $205.26 | +43.4% | $108.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVLN AVALYN PHARMA INC | 1.32% | $32.92 | $28.49 | -13.5% | $76.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 1.05% | — | — | — | $70M | |
DYN DYNE THERAPEUTICS INC | 0.90% | $18.83 | $16.11 | -14.5% | $43.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BIIB BIOGEN INC | 0.90% | $216.06 | $225.88 | +4.5% | $62.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IMVT IMMUNOVANT INC | 0.79% | $24.48 | $33.78 | +38.0% | $45.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
UNH UNITEDHEALTH GROUP INC | 0.73% | $415.63 | $367.08 | -11.7% | $42.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XBIPut SS SPDR S&P BIOTECH ETF | 0.71% | — | — | — | $47.5M |
IONS IONIS PHARMACEUTICALS INC | 0.67% | $75.55 | $44.65 | -40.9% | $25.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
STRO SUTRO BIOPHARMA INC | 0.65% | $28.66 | $16.11 | -43.8% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANRO ALTO NEUROSCIENCE INC | 0.64% | $17.26 | $25.53 | +47.9% | $41.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
JAZZ JAZZ PHARMACEUTICALS PLC | 0.61% | $170.00 | $231.52 | +36.2% | $39.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRVS CORVUS PHARMACEUTICALS INC | 0.60% | $11.91 | $11.52 | -3.3% | $30.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SION SIONNA THERAPEUTICS INC | 0.60% | $19.60 | $5.26 | -73.2% | $4.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTMX CYTOMX THERAPEUTICS INC | 0.59% | $2.65 | $2.72 | +2.5% | $28.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AORT ARTIVION INC | 0.59% | $13.65 | $22.82 | +67.2% | $39.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XFOR X4 PHARMACEUTICALS INC | 0.56% | $4.11 | $2.90 | -29.4% | $23M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CORT CORCEPT THERAPEUTICS INC | 0.52% | $81.10 | $115.23 | +42.1% | $45.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RGEN REPLIGEN CORP | 0.51% | $134.28 | $192.23 | +43.2% | $47.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVR ANTERIS TECHNOLOGIES GLOBAL | 0.51% | $5.56 | $7.77 | +39.6% | $26.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RAPP RAPPORT THERAPEUTICS INC | 0.48% | $31.46 | $33.60 | +6.8% | $26M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
36322Q206 DAMORA THERAPEUTICS INC | 0.48% | $25.90 | $26.01 | +0.4% | $31.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CRL CHARLES RIVER LABORATORIES | 0.48% | $226.79 | $295.01 | +30.1% | $41.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AXSM AXSOME THERAPEUTICS INC | 0.44% | $82.27 | $184.39 | +124.1% | $21.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EYPTPut EYEPOINT INC | 0.43% | — | — | — | $28.6M |
DBVT DBV TECHNOLOGIES SA-SPON ADR | 0.41% | $19.02 | $11.76 | -38.2% | $19.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
IRTC IRHYTHM HOLDINGS INC | 0.40% | $143.84 | $113.66 | -21.0% | $25.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADPT ADAPTIVE BIOTECHNOLOGIES | 0.39% | $20.50 | $28.90 | +41.0% | $35.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SABS SAB BIOTHERAPEUTICS INC | 0.39% | $3.82 | $3.17 | -17.0% | $21M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
DHR DANAHER CORP | 0.37% | $190.48 | $221.55 | +16.3% | $28.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TENX TENAX THERAPEUTICS INC | 0.37% | $14.79 | $56.70 | +283.2% | $96.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.36% | — | — | — | $24.1M | |
SLSPut SELLAS LIFE SCIENCES GROUP I | 0.33% | — | — | — | $22.1M |
NAUT NAUTILUS BIOTECHNOLOGY INC | 0.33% | $6.31 | $1.42 | -77.5% | $16.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OBIO ORCHESTRA BIOMED HOLDINGS IN | 0.33% | $10.64 | $6.22 | -41.6% | $31.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ISRG INTUITIVE SURGICAL INC | 0.31% | $468.73 | $406.63 | -13.2% | $21.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ANL ADLAI NORTYE GROUP LTD | 0.31% | $11.50 | $16.00 | +39.1% | $28.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CTNM CONTINEUM THERAPEUTICS INC-A | 0.31% | $14.38 | $13.42 | -6.7% | $16.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NVCT NUVECTIS PHARMA INC | 0.28% | $18.39 | $21.12 | +14.8% | $21.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PALI PALISADE BIO INC | 0.26% | $2.35 | $1.35 | -42.6% | $11.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OMDA OMADA HEALTH INC | 0.26% | $18.30 | $21.95 | +19.9% | $17.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
LONA LEONABIO INC | 0.26% | $6.49 | $3.57 | -45.0% | $6.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EOLS EVOLUS INC | 0.26% | $5.46 | $8.00 | +46.5% | $19.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.25% | — | — | — | $16.9M | |
IVVD INVIVYD INC | 0.24% | $2.47 | $0.87 | -64.8% | $16.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.22% | — | — | — | $14.6M | |
MIRM MIRUM PHARMACEUTICALS INC | 0.20% | $117.07 | $85.48 | -27.0% | $9.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZN SURROZEN INC | 0.20% | $27.40 | $32.18 | +17.5% | $16.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BBNX BETA BIONICS INC | 0.20% | $18.64 | $18.98 | +1.8% | $15.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
| 0.18% | — | — | — | $12M | |
AXGN AXOGEN INC | 0.17% | $32.73 | $41.92 | +28.1% | $10.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OSCR OSCAR HEALTH INC - CLASS A | 0.17% | $28.52 | $30.84 | +8.1% | $12.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OCS OCULIS HOLDING AG | 0.17% | $17.59 | $9.34 | -46.9% | $7.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SPTX SEAPORT THERAPEUTICS INC | 0.16% | $21.72 | $20.17 | -7.1% | $10.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
VRDN VIRIDIAN THERAPEUTICS INC | 0.16% | $26.42 | $20.59 | -22.1% | $12M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BSX BOSTON SCIENTIFIC CORP | 0.16% | $42.68 | $43.65 | +2.3% | $10.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BLLN BILLIONTOONE INC CL A | 0.16% | $81.24 | $106.44 | +31.0% | $9.2M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ABVX ABIVAX SA-ADR | 0.15% | $92.50 | $99.02 | +7.0% | $7.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
NTRA NATERA INC | 0.14% | $271.45 | $413.31 | +52.3% | $14.3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENGN ENGENE THERAPEUTICS INC | 0.13% | $1.73 | $2.00 | +15.6% | $9.6M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RACC RESEARCH ALLIANCE CORP CL A | 0.12% | $10.70 | $10.83 | +1.2% | $8.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AGMB AGOMAB THERAPEUTICS NV | 0.12% | $10.49 | $11.10 | +5.8% | $6.7M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CGEM CULLINAN THERAPEUTICS INC | 0.12% | $18.21 | $15.35 | -15.7% | $6.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
QURE UNIQURE NV | 0.12% | $46.06 | $24.16 | -47.5% | $4.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MOBI MOBIA MEDICAL INC | 0.11% | $13.40 | $9.45 | -29.5% | $4.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADGM ADAGIO MEDICAL HOLDINGS INC | 0.10% | $2.57 | $0.15 | -94.1% | $1.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
GH GUARDANT HEALTH INC | 0.09% | $97.58 | $178.36 | +82.8% | $7.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
PHAT PHATHOM PHARMACEUTICALS INC | 0.09% | $11.11 | $7.30 | -34.3% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OTLK OUTLOOK THERAPEUTICS INC | 0.07% | $1.59 | $0.57 | -63.9% | $1.8M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
COGT COGENT BIOSCIENCES INC | 0.07% | $35.52 | $32.02 | -9.9% | $3.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
EDSA EDESA BIOTECH INC | 0.07% | $5.23 | $4.21 | -19.5% | $2.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
AVTX AVALO THERAPEUTICS INC | 0.06% | $11.83 | $15.33 | +29.6% | $3.4M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
TWST TWIST BIOSCIENCE CORP | 0.06% | $47.52 | $193.24 | +306.6% | $7.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CBIO CRESCENT BIOPHARMA INC | 0.06% | $16.14 | $14.59 | -9.6% | $3M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XERS XERIS BIOPHARMA HOLDINGS INC | 0.06% | $7.92 | $9.56 | +20.7% | $4.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
OM OUTSET MEDICAL INC | 0.05% | $11.06 | $3.00 | -72.9% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
BDSX BIODESIX INC | 0.04% | $22.55 | $22.55 | 0.0% | $2.5M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
RVMDW REVOLUTION MEDICINES INC-28 | 0.04% | $0.33 | $11.44 | +3,366.7% | $2.9M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CNTB CONNECT BIOPHARMA HOLDINGS L | 0.03% | $2.82 | $1.10 | -61.0% | $872K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
KPRX KIORA PHARMACEUTICALS INC | 0.02% | $2.63 | $2.56 | -2.7% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
MDLN MEDLINE INC-CL A | 0.02% | $42.00 | $34.70 | -17.4% | $971.6K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ADMA ADMA BIOLOGICS INC | 0.01% | $8.43 | $10.03 | +19.0% | $1.1M |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
CPIX CUMBERLAND PHARMACEUTICALS | 0.01% | $7.96 | $6.48 | -18.6% | $628.4K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
XGN EXAGEN INC | 0.01% | $3.00 | $8.13 | +171.0% | $934.1K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
ENSC ENSYSCE BIOSCIENCES INC | 0.00% | $8.14 | $0.42 | -94.9% | $36K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
SRZNW SURROZEN INC-CW25 | 0.00% | — | $0.02 | — | $2.7K |
Quarter-end priceAvg. cost (est.)BoughtSold | |||||
Average cost is an estimate, not the investor's actual purchase price: every quarter the share count rose, the added shares are counted at that quarter-end's 13F price, and sales keep the average. Latest price is the most recent 13F quarter-end price (Sep 30, 2026), and value is shares × latest price.
Changes in shares
Change in shares held vs Mar 31, 2026, for the 20 largest positions that changed. Bars are capped at ±100%; the label shows the actual change.
Sold out this quarter
Held on Mar 31, 2026 and not reported for Q2 2026.
| Stock | Prior weight | Prior shares | Prior value | Change |
|---|---|---|---|---|
| 04351P101 ASCENDIS PHARMA A/S | 6.84% | 1,531,421 | $350.3M | EXIT |
| CNTA CENTESSA PHARMACEUTICALS LTD | 4.08% | 5,258,903 | $208.9M | EXIT |
| 29286M105 ENGENE HOLDINGS INC | 0.78% | 5,827,506 | $39.7M | EXIT |
| DAWN DAY ONE BIOPHARMACEUTICALS I | 0.74% | 1,755,799 | $37.6M | EXIT |
| DRUG BRIGHT MINDS BIOSCIENCES INC | 0.54% | 377,544 | $27.5M | EXIT |
| BLTE BELITE BIO INC - ADR | 0.47% | 151,979 | $24.2M | EXIT |
| EVMN EVOMMUNE INC | 0.20% | 448,350 | $10.3M | EXIT |
| NMRA NEUMORA THERAPEUTICS INC | 0.19% | 5,104,097 | $10M | EXIT |
| NBIX NEUROCRINE BIOSCIENCES INC | 0.17% | 65,050 | $8.6M | EXIT |
| IRD OPUS GENETICS INC | 0.16% | 1,835,842 | $8.4M | EXIT |
| OCULCall OCULAR THERAPEUTIX INC | 0.08% | 500,000 | $4.2M | EXIT |
| IKT INHIBIKASE THERAPEUTICS INC | 0.08% | 2,315,000 | $3.9M | EXIT |
| APLS APELLIS PHARMACEUTICALS INC | 0.06% | 80,956 | $3.3M | EXIT |
| PTN PALATIN TECHNOLOGIES INC | 0.02% | 61,945 | $1.1M | EXIT |
SEC filings for Q2 2026
- 13F-HR 0001012975-26-000777 · accepted Aug 14, 2026, 20:11 UTC